{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:40:29Z","timestamp":1784043629300,"version":"3.55.0"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Psoriatic arthritis (PsA) is a complex inflammatory disease characterised by a combination of cutaneous and musculoskeletal symptoms, which complicates both diagnosis and management. Despite advances in targeted therapy, the treatment of PsA remains challenging, with up to 40% of patients experiencing inadequate response. Predictive biomarkers may serve as valuable tools to help clinicians select the most appropriate therapy at the optimal time. However, despite substantial research activity, the current evidence remains inconclusive. Moreover, biomarkers that predict treatment response may differ from those that dynamically change in response to therapy. In this narrative review we therefore examine both biomarkers with potential predictive value and those that demonstrate treatment-related changes over time. Multi-omics approaches have enhanced understanding of the molecular determinants of therapeutic response. Most genetic analyses have investigated TNF inhibitor response, whereas certain transcriptomic studies highlight genes related to apoptosis and immune-mediated pathways as key contributors to therapeutic response across different treatments and throughout the treatment course. Several non-coding RNAs and protein panels have also shown promise as indicators of treatment outcome, but metabolomic studies remain scarce. Reported molecular signatures nonetheless vary widely, likely reflecting disease heterogeneity as well as differences in treatment modalities, study design, and outcome measures, and are summarised herein. Future studies integrating multi-omics and computational frameworks are essential to validate candidate biomarkers and facilitate personalised treatment strategies in PsA.<\/jats:p>","DOI":"10.1038\/s41397-026-00410-8","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:07:56Z","timestamp":1778857676000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Exploring biomarkers for treatment response in psoriatic arthritis: a focus on multi-omics technologies"],"prefix":"10.1038","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2232-4017","authenticated-orcid":false,"given":"Moshiur Rahman","family":"Khasru","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahdia Afiifah","family":"Abdul Jalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9829-792X","authenticated-orcid":false,"given":"Nisha","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3316-2527","authenticated-orcid":false,"given":"Anne","family":"Barton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1016-6851","authenticated-orcid":false,"given":"Paul","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5062-5779","authenticated-orcid":false,"given":"James","family":"Bluett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"410_CR1","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","volume":"80","author":"F Alinaghi","year":"2019","unstructured":"Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D, et al. Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80:251\u201365.e19.","journal-title":"J Am Acad Dermatol"},{"key":"410_CR2","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","volume":"391","author":"DJ Veale","year":"2018","unstructured":"Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018;391:2273\u201384.","journal-title":"Lancet"},{"key":"410_CR3","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/j.1468-3083.2009.03463.x","volume":"24","author":"E Christophers","year":"2010","unstructured":"Christophers E, Barker JN, Griffiths CE, Daud\u00e9n E, Milligan G, Molta C, et al. The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. J Eur Acad Dermatol Venereol. 2010;24:548\u201354.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"410_CR4","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3899\/jrheum.110845","volume":"39","author":"W Tillett","year":"2012","unstructured":"Tillett W, Costa L, Jadon D, Wallis D, Cavill C, McHugh J, et al. The ClASsification for Psoriatic ARthritis (CASPAR) criteria-a retrospective feasibility, sensitivity, and specificity study. J Rheumatol. 2012;39:154\u20136.","journal-title":"J Rheumatol"},{"key":"410_CR5","first-page":"1509","volume":"22","author":"A Pinter","year":"2024","unstructured":"Pinter A, Hofmann M, Kaufmann R, M\u00fcller-Stahl J, K\u00f6nig A. Screening of psoriatic arthritis by dermatologists - a German nationwide survey. J Dtsch Dermatol Ges. 2024;22:1509\u201316.","journal-title":"J Dtsch Dermatol Ges"},{"key":"410_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2019.108318","volume":"211","author":"J Pouw","year":"2020","unstructured":"Pouw J, Leijten E, Radstake T, Boes M. Emerging molecular biomarkers for predicting therapy response in psoriatic arthritis: A review of literature. Clin Immunol. 2020;211:108318.","journal-title":"Clin Immunol"},{"key":"410_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3390\/proteomes12030025","volume":"12","author":"R Vitorino","year":"2024","unstructured":"Vitorino R. Transforming Clinical Research: The Power of High-Throughput Omics Integration. Proteomes. 2024;12:25.","journal-title":"Proteomes"},{"key":"410_CR8","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/ard-2024-225531","volume":"83","author":"L Gossec","year":"2024","unstructured":"Gossec L, Kerschbaumer A, Ferreira RJO, Aletaha D, Baraliakos X, Bertheussen H, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Annals of the Rheumatic Diseases. 2024;83:706\u201319.","journal-title":"Annals of the Rheumatic Diseases"},{"key":"410_CR9","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1093\/rheumatology\/keac295","volume":"61","author":"L Tucker","year":"2022","unstructured":"Tucker L, Allen A, Chandler D, Ciurtin C, Dick A, Foulkes A, et al. The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs. Rheumatology. 2022;61:e255\u2013e66.","journal-title":"Rheumatology"},{"key":"410_CR10","doi-asserted-by":"publisher","first-page":"113074","DOI":"10.1016\/j.biopha.2022.113074","volume":"150","author":"Z Zhao","year":"2022","unstructured":"Zhao Z, Hua Z, Luo X, Li Y, Yu L, Li M, et al. Application and pharmacological mechanism of methotrexate in rheumatoid arthritis. Biomedicine & Pharmacotherapy. 2022;150:113074.","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"410_CR11","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.semarthrit.2016.09.005","volume":"46","author":"K Aaltonen","year":"2017","unstructured":"Aaltonen K, Heinonen A, Joensuu J, Parmanne P, Karjalainen A, Varjolahti-Lehtinen T, et al. Effectiveness and drug survival of TNF-inhibitors in the treatment of psoriatic arthritis: A prospective cohort study. Semin Arthritis Rheum. 2017;46:732\u20139.","journal-title":"Semin Arthritis Rheum"},{"key":"410_CR12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.cyto.2016.08.014","volume":"101","author":"H Mitoma","year":"2018","unstructured":"Mitoma H, Horiuchi T, Tsukamoto H, Ueda N. Molecular mechanisms of action of anti-TNF-\u03b1 agents \u2013 Comparison among therapeutic TNF-\u03b1 antagonists. Cytokine. 2018;101:56\u201363.","journal-title":"Cytokine"},{"key":"410_CR13","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.ard.2025.10.011","volume":"85","author":"L Eder","year":"2025","unstructured":"Eder L, Dang S, Caucheteux SM, Li X, Thib S, Ganatra D, et al. CD3+ immune cell endotypes are associated with PsA disease phenotype and response to advanced therapy: an integrated mass cytometry and proteomics cohort study. Ann Rheum Dis. 2025;85:457\u201366.","journal-title":"Ann Rheum Dis"},{"key":"410_CR14","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1136\/annrheumdis-2020-218186","volume":"80","author":"A Nerviani","year":"2021","unstructured":"Nerviani A, Boutet MA, Tan WSG, Goldmann K, Purkayastha N, Lajtos TA, et al. IL-23 skin and joint profiling in psoriatic arthritis: novel perspectives in understanding clinical responses to IL-23 inhibitors. Ann Rheum Dis. 2021;80:591\u20137.","journal-title":"Ann Rheum Dis"},{"key":"410_CR15","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3111\/13696998.2013.768530","volume":"16","author":"NY Kirson","year":"2013","unstructured":"Kirson NY, Rao S, Birnbaum HG, Kantor E, Wei RS, Cifaldi M. Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis. J Med Econ. 2013;16:479\u201389.","journal-title":"J Med Econ"},{"key":"410_CR16","doi-asserted-by":"publisher","first-page":"1759720x2110140","DOI":"10.1177\/1759720X211014010","volume":"13","author":"C Magee","year":"2021","unstructured":"Magee C, Jethwa H, FitzGerald OM, Jadon DR. Biomarkers predictive of treatment response in psoriasis and psoriatic arthritis: a systematic review. Ther Adv Musculoskelet Dis. 2021;13:1759720x211014010.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"410_CR17","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.autrev.2014.01.050","volume":"13","author":"E Suzuki","year":"2014","unstructured":"Suzuki E, Mellins ED, Gershwin ME, Nestle FO, Adamopoulos IE. The IL-23\/IL-17 axis in psoriatic arthritis. Autoimmun Rev. 2014;13:496\u2013502.","journal-title":"Autoimmun Rev"},{"key":"410_CR18","doi-asserted-by":"publisher","first-page":"596086","DOI":"10.3389\/fimmu.2020.596086","volume":"11","author":"M Vecellio","year":"2021","unstructured":"Vecellio M, Hake VX, Davidson C, Carena MC, Wordsworth BP, Selmi C. The IL-17\/IL-23 Axis and Its Genetic Contribution to Psoriatic Arthritis. Frontiers in Immunology. 2021;11:596086.","journal-title":"Frontiers in Immunology"},{"key":"410_CR19","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1080\/1744666X.2025.2522950","volume":"21","author":"F Caso","year":"2025","unstructured":"Caso F, Saviano A, Marigliano N, Casillo GM, Peluso M, Ciccone M, et al. IL-17A in psoriatic arthritis: mechanistic insights, clinical implications, and advances in therapeutic strategies. Expert Rev Clin Immunol. 2025;21:1055\u201371.","journal-title":"Expert Rev Clin Immunol"},{"key":"410_CR20","doi-asserted-by":"publisher","first-page":"e003855","DOI":"10.1136\/rmdopen-2023-003855","volume":"10","author":"LC Coates","year":"2024","unstructured":"Coates LC, Landew\u00e9 R, McInnes IB, Mease PJ, Ritchlin CT, Tanaka Y, et al. Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL. RMD Open. 2024;10:e003855.","journal-title":"RMD Open"},{"key":"410_CR21","doi-asserted-by":"publisher","first-page":"535","DOI":"10.4161\/mabs.3.6.17815","volume":"3","author":"JM Benson","year":"2011","unstructured":"Benson JM, Peritt D, Scallon BJ, Heavner GA, Shealy DJ, Giles-Komar JM, et al. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs. 2011;3:535\u201345.","journal-title":"MAbs"},{"key":"410_CR22","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2217\/pgs-2016-0122","volume":"18","author":"R Prieto-P\u00e9rez","year":"2017","unstructured":"Prieto-P\u00e9rez R, Llamas-Velasco M, Cabaleiro T, Solano-L\u00f3pez G, M\u00e1rquez B, Rom\u00e1n M, et al. Pharmacogenetics of Ustekinumab in Patients with Moderate-to-severe Plaque Psoriasis. Pharmacogenomics. 2017;18:157\u201364.","journal-title":"Pharmacogenomics"},{"key":"410_CR23","volume":"15","author":"CK Kerut","year":"2023","unstructured":"Kerut CK, Wagner MJ, Daniel CP, Fisher C, Henderson EJ, Burroughs CR, et al. Guselkumab, a Novel Monoclonal Antibody Inhibitor of the p19 Subunit of IL-23, for Psoriatic Arthritis and Plaque Psoriasis: A Review of Its Mechanism, Use, and Clinical Effectiveness. Cureus. 2023;15:e51405.","journal-title":"Cureus"},{"key":"410_CR24","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1136\/annrheumdis-2021-221019","volume":"81","author":"LE Kristensen","year":"2022","unstructured":"Kristensen LE, Keiserman M, Papp K, McCasland L, White D, Lu W, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial. Ann Rheum Dis. 2022;81:225\u201331.","journal-title":"Ann Rheum Dis"},{"key":"410_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.614255","volume":"12","author":"D McGonagle","year":"2021","unstructured":"McGonagle D, Watad A, Sharif K, Bridgewood C. Why Inhibition of IL-23 Lacked Efficacy in Ankylosing Spondylitis. Front Immunol. 2021;12:614255.","journal-title":"Front Immunol"},{"key":"410_CR26","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1136\/annrheumdis-2018-213654","volume":"78","author":"S Siebert","year":"2019","unstructured":"Siebert S, Millar NL, McInnes IB. Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation? Annals of the Rheumatic Diseases. 2019;78:1015\u20138.","journal-title":"Annals of the Rheumatic Diseases"},{"key":"410_CR27","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","volume":"6","author":"X Hu","year":"2021","unstructured":"Hu X, li J, Fu M, Zhao X, Wang W. The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduction and Targeted Therapy. 2021;6:402.","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"410_CR28","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/s13075-015-0771-6","volume":"17","author":"M Perez-Aso","year":"2015","unstructured":"Perez-Aso M, Montesinos MC, Mediero A, Wilder T, Schafer PH, Cronstein B. Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors. Arthritis Res Ther. 2015;17:249.","journal-title":"Arthritis Res Ther"},{"key":"410_CR29","doi-asserted-by":"publisher","first-page":"e003809","DOI":"10.1136\/rmdopen-2023-003809","volume":"10","author":"S Singla","year":"2024","unstructured":"Singla S, Ribeiro A, Torgutalp M, Mease PJ, Proft F. Difficult-to-treat psoriatic arthritis (D2T PsA): a scoping literature review informing a GRAPPA research project. RMD Open. 2024;10:e003809.","journal-title":"RMD Open"},{"key":"410_CR30","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s40268-017-0215-7","volume":"17","author":"L Costa","year":"2017","unstructured":"Costa L, Perricone C, Chimenti MS, Del Puente A, Caso P, Peluso R, et al. Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence. Drugs R D. 2017;17:509\u201322.","journal-title":"Drugs R D"},{"key":"410_CR31","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.berh.2019.03.001","volume":"32","author":"F Oliver","year":"2018","unstructured":"Oliver F, Christopher R. Opportunites and challenges in the treatment of psoriatic arthritis. Best Practice & Research Clinical Rheumatology. 2018;32:440\u201352.","journal-title":"Best Practice & Research Clinical Rheumatology"},{"key":"410_CR32","doi-asserted-by":"publisher","first-page":"159","DOI":"10.46497\/ArchRheumatol.2024.10710","volume":"39","author":"C Lopez-Medina","year":"2024","unstructured":"Lopez-Medina C, Kalyoncu U, Gossec L. Unmet needs in psoriatic arthritis, a narrative review. Arch Rheumatol. 2024;39:159\u201371.","journal-title":"Arch Rheumatol"},{"key":"410_CR33","doi-asserted-by":"publisher","first-page":"e003612","DOI":"10.1136\/rmdopen-2023-003612","volume":"9","author":"F Fagni","year":"2023","unstructured":"Fagni F, Mutlu MY, Temiz SA, Minopoulou I, Krieter M, Schett G, et al. Tolerability of low to moderate biomechanical stress during leisure sport activity in patients with psoriasis and psoriatic arthritis. RMD Open. 2023;9:e003612.","journal-title":"RMD Open"},{"key":"410_CR34","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1007\/s10067-023-06605-9","volume":"42","author":"A Kumthekar","year":"2023","unstructured":"Kumthekar A, Ashrafi M, Deodhar A. Difficult to treat psoriatic arthritis - how should we manage? Clin Rheumatol. 2023;42:2251\u201365.","journal-title":"Clin Rheumatol"},{"key":"410_CR35","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40273-018-0618-5","volume":"36","author":"LS D\u2019Angiolella","year":"2018","unstructured":"D\u2019Angiolella LS, Cortesi PA, Lafranconi A, Micale M, Mangano S, Cesana G, et al. Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: A Systematic Literature Review. Pharmacoeconomics. 2018;36:567\u201389.","journal-title":"Pharmacoeconomics"},{"key":"410_CR36","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.3390\/cancers14122854","volume":"14","author":"E Mulder","year":"2022","unstructured":"Mulder E, Johansson I, Gr\u00fcnhagen DJ, Tempel D, Rentroia-Pacheco B, Dwarkasing JT, et al. Using a Clinicopathologic and Gene Expression (CP-GEP) Model to Identify Stage I-II Melanoma Patients at Risk of Disease Relapse. Cancers (Basel). 2022;14:2854.","journal-title":"Cancers (Basel)"},{"key":"410_CR37","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s43586-021-00056-9","volume":"1","author":"E Uffelmann","year":"2021","unstructured":"Uffelmann E, Huang QQ, Munung NS, de Vries J, Okada Y, Martin AR, et al. Genome-wide association studies. Nature Reviews Methods Primers. 2021;1:59.","journal-title":"Nature Reviews Methods Primers"},{"key":"410_CR38","doi-asserted-by":"publisher","first-page":"vi38","DOI":"10.1093\/rheumatology\/keab504","volume":"60","author":"A Elliott","year":"2021","unstructured":"Elliott A, McGonagle D, Rooney M. Integrating imaging and biomarker assessment to better define psoriatic arthritis and predict response to biologic therapy. Rheumatology (Oxford). 2021;60:vi38\u2013vi52.","journal-title":"Rheumatology (Oxford)"},{"key":"410_CR39","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.3899\/jrheum.091311","volume":"37","author":"V Chandran","year":"2010","unstructured":"Chandran V, Siannis F, Rahman P, Pellett FJ, Farewell VT, Gladman DD. Folate pathway enzyme gene polymorphisms and the efficacy and toxicity of methotrexate in psoriatic arthritis. J Rheumatol. 2010;37:1508\u201312.","journal-title":"J Rheumatol"},{"key":"410_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.869912","volume":"9","author":"J Zhu","year":"2022","unstructured":"Zhu J, Wang Z, Tao L, Han L, Huang Q, Fang X, et al. MTHFR Gene Polymorphism Association With Psoriatic Arthritis Risk and the Efficacy and Hepatotoxicity of Methotrexate in Psoriasis. Front Med (Lausanne). 2022;9:869912.","journal-title":"Front Med (Lausanne)"},{"key":"410_CR41","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41397-018-0040-6","volume":"18","author":"J Massey","year":"2018","unstructured":"Massey J, Plant D, Hyrich K, Morgan AW, Wilson AG, Spiliopoulou A, et al. Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis. The Pharmacogenomics Journal. 2018;18:657\u201364.","journal-title":"The Pharmacogenomics Journal"},{"key":"410_CR42","doi-asserted-by":"publisher","first-page":"5793","DOI":"10.3390\/ijms25115793","volume":"25","author":"RF Al-Sofi","year":"2024","unstructured":"Al-Sofi RF, Bergmann MS, Nielsen CH, Andersen V, Skov L, Loft N. The Association between Genetics and Response to Treatment with Biologics in Patients with Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, and Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences. 2024;25:5793.","journal-title":"International Journal of Molecular Sciences"},{"key":"410_CR43","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1111\/jdv.19782","volume":"38","author":"E Mu\u00f1oz-Aceituno","year":"2024","unstructured":"Mu\u00f1oz-Aceituno E, Butr\u00f3n-Bris B, Ovejero-Benito MC, Sahuquillo-Torralba A, Baniandr\u00e9s Rodr\u00edguez O, Herrera-Acosta E, et al. Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice. Journal of the European Academy of Dermatology and Venereology. 2024;38:1783\u201390.","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"key":"410_CR44","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/jdv.15787","volume":"34","author":"LJ van Vugt","year":"2020","unstructured":"van Vugt LJ, van den Reek J, Meulewaeter E, Hakobjan M, Heddes N, Traks T, et al. Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts. J Eur Acad Dermatol Venereol. 2020;34:112\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"410_CR45","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/jpm11010020","volume":"11","author":"DA Verbenko","year":"2020","unstructured":"Verbenko DA, Karamova AE, Artamonova OG, Deryabin DG, Rakitko A, Chernitsov A, et al. Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis. J Pers Med. 2020;11:20.","journal-title":"J Pers Med"},{"key":"410_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms22031422","volume":"22","author":"S Supplitt","year":"2021","unstructured":"Supplitt S, Karpinski P, Sasiadek M, Laczmanska I. Current Achievements and Applications of Transcriptomics in Personalized Cancer Medicine. International Journal of Molecular Sciences. 2021;22:1\u201322.","journal-title":"International Journal of Molecular Sciences"},{"key":"410_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-78866-2","volume":"10","author":"S Rahmati","year":"2020","unstructured":"Rahmati S, O\u2019Rielly DD, Li Q, Codner D, Dohey A, Jenkins K, et al. Rho-GTPase pathways may differentiate treatment response to TNF-alpha and IL-17A inhibitors in psoriatic arthritis. Sci Rep. 2020;10:21703.","journal-title":"Sci Rep"},{"key":"410_CR48","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1002\/acr2.11589","volume":"5","author":"S Siebert","year":"2023","unstructured":"Siebert S, Sweet KM, Ritchlin CT, Hsia EC, Kollmeier AP, Xu XL, et al. Guselkumab Modulates Differentially Expressed Genes in Blood of Patients With Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo-Controlled Trials. ACR open rheumatology. 2023;5:490\u20138.","journal-title":"ACR open rheumatology"},{"key":"410_CR49","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1093\/rheumatology\/kead007","volume":"62","author":"AL Cross","year":"2023","unstructured":"Cross AL, Hawkes J, Frankland H, Mediana A, Wright HL, Goodson NJ, et al. Neutrophil function following treatment of psoriatic arthritis patients with secukinumab: altered cytokine signalling but no impairment of host defence. Rheumatology (Oxford). 2023;62:3025\u201334.","journal-title":"Rheumatology (Oxford)"},{"key":"410_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1274539","volume":"14","author":"MM Angioni","year":"2023","unstructured":"Angioni MM, Floris A, Cangemi I, Congia M, Chessa E, Naitza MR, et al. Molecular profiling of clinical remission in psoriatic arthritis reveals dysregulation of FOS and CCDC50 genes: a gene expression study. Front Immunol. 2023;14:1274539.","journal-title":"Front Immunol"},{"key":"410_CR51","doi-asserted-by":"publisher","first-page":"244","DOI":"10.5114\/ada.2019.91504","volume":"38","author":"B Grabarek","year":"2021","unstructured":"Grabarek B, Wcis\u0142o-Dziadecka D, Strza\u0142ka-Mrozik B, Gola J, Plewka A. Ustekinumab therapy changes the transcriptional activity pattern of TGF-\u03b21-3 genes. Postepy Dermatol Alergol. 2021;38:244\u20138.","journal-title":"Postepy Dermatol Alergol"},{"key":"410_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.964274","volume":"13","author":"A Grivas","year":"2022","unstructured":"Grivas A, Grigoriou M, Malissovas N, Sentis G, Filia A, Flouda S, et al. Combined \u2013 whole blood and skin fibroblasts- transcriptomic analysis in Psoriatic Arthritis reveals molecular signatures of activity, resistance and early response to treatment. Frontiers in Immunology. 2022;13:964274.","journal-title":"Frontiers in Immunology"},{"key":"410_CR53","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s43440-020-00068-4","volume":"72","author":"A Krawczyk","year":"2020","unstructured":"Krawczyk A, Strza\u0142ka-Mrozik B, Grabarek B, Wcis\u0142o-Dziadecka D, Kimsa-Dudek M, Kruszniewska-Rajs C, et al. mRNA level of ROCK1, RHOA, and LIMK2 as genes associated with apoptosis in evaluation of effectiveness of adalimumab treatment. Pharmacol Rep. 2020;72:389\u201399.","journal-title":"Pharmacol Rep"},{"key":"410_CR54","doi-asserted-by":"publisher","first-page":"330","DOI":"10.2174\/1389201023666220628111644","volume":"24","author":"A Krawczyk","year":"2023","unstructured":"Krawczyk A, Strza\u0142ka-Mrozik B, Juszczyk K, Kimsa-Dudek M, Wcis\u0142o-Dziadecka D, Gola J. The MAP2K2 Gene as Potential Diagnostic Marker in Monitoring Adalimumab Therapy of Psoriatic Arthritis. Curr Pharm Biotechnol. 2023;24:330\u201340.","journal-title":"Curr Pharm Biotechnol"},{"key":"410_CR55","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13277","volume":"33","author":"A Krawczyk","year":"2020","unstructured":"Krawczyk A, Strza\u0142ka-Mrozik B, Wcis\u0142o-Dziadecka D, Grabarek B, Kimsa-Dudek M, Gola J. Adalimumab changes the expression profile of selected BCL-2 family genes. Dermatol Ther. 2020;33:e13277.","journal-title":"Dermatol Ther"},{"key":"410_CR56","doi-asserted-by":"publisher","first-page":"262","DOI":"10.5114\/ada.2020.94847","volume":"37","author":"D Wcis\u0142o-Dziadecka","year":"2020","unstructured":"Wcis\u0142o-Dziadecka D, Grabarek B, Swinarew AS, Rozwadowska B, Zmarz\u0142y N, Gola J. Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis. Postepy Dermatol Alergol. 2020;37:262\u20138.","journal-title":"Postepy Dermatol Alergol"},{"key":"410_CR57","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/1440-1681.12294","volume":"41","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Meng XM, Huang XR, Wang XJ, Yang L, Lan HY. Transforming growth factor-\u03b21 mediates psoriasis-like lesions via a Smad3-dependent mechanism in mice. Clin Exp Pharmacol Physiol. 2014;41:921\u201332.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"410_CR58","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3389\/fmolb.2021.662047","volume":"8","author":"AL Carvalho","year":"2021","unstructured":"Carvalho AL, Hedrich CM. The Molecular Pathophysiology of Psoriatic Arthritis\u2014The Complex Interplay Between Genetic Predisposition, Epigenetics Factors, and the Microbiome. Frontiers in Molecular Biosciences. 2021;8:190.","journal-title":"Frontiers in Molecular Biosciences"},{"key":"410_CR59","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaut.2016.12.002","volume":"78","author":"RA Pollock","year":"2017","unstructured":"Pollock RA, Abji F, Gladman DD. Epigenetics of psoriatic disease: A systematic review and critical appraisal. Journal of Autoimmunity. 2017;78:29\u201338.","journal-title":"Journal of Autoimmunity"},{"key":"410_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01159-9","volume":"19","author":"X Yang","year":"2020","unstructured":"Yang X, Liu M, Li M, Zhang S, Hiju H, Sun J, et al. Epigenetic modulations of noncoding RNA: a novel dimension of Cancer biology. Mol Cancer. 2020;19:64.","journal-title":"Mol Cancer"},{"key":"410_CR61","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nri.2016.40","volume":"16","author":"A Mehta","year":"2016","unstructured":"Mehta A, Baltimore D. MicroRNAs as regulatory elements in immune system logic. Nat Rev Immunol. 2016;16:279\u201394.","journal-title":"Nat Rev Immunol"},{"key":"410_CR62","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1158\/1078-0432.CCR-14-2011","volume":"21","author":"K Kleivi Sahlberg","year":"2015","unstructured":"Kleivi Sahlberg K, Bottai G, Naume B, Burwinkel B, Calin GA, B\u00f8rresen-Dale AL, et al. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients. Clin Cancer Res. 2015;21:1207\u201314.","journal-title":"Clin Cancer Res"},{"key":"410_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2020.100044","volume":"3","author":"Y Zou","year":"2020","unstructured":"Zou Y, Xu H. Involvement of long noncoding RNAs in the pathogenesis of autoimmune diseases. J Transl Autoimmun. 2020;3:100044.","journal-title":"J Transl Autoimmun"},{"key":"410_CR64","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.3899\/jrheum.190602","volume":"47","author":"SM Wade","year":"2020","unstructured":"Wade SM, McGarry T, Wade SC, Fearon U, Veale DJ. Serum MicroRNA Signature as a Diagnostic and Therapeutic Marker in Patients with Psoriatic Arthritis. J Rheumatol. 2020;47:1760\u20137.","journal-title":"J Rheumatol"},{"key":"410_CR65","first-page":"113","volume":"35","author":"G Ciancio","year":"2017","unstructured":"Ciancio G, Ferracin M, Saccenti E, Bagnari V, Farina I, Furini F, et al. Characterisation of peripheral blood mononuclear cell microRNA in early onset psoriatic arthritis. Clin Exp Rheumatol. 2017;35:113\u201321.","journal-title":"Clin Exp Rheumatol"},{"key":"410_CR66","unstructured":"Machhar R, Ye JY, Pollock R, Gladman D, editors. miR-21-5p Expression as a Marker of Treatment Response in Psoriatic Arthritis Patients. 2018 ACR\/ARHP Annual Meeting; 2019: Arthritis & Rheumatology."},{"key":"410_CR67","unstructured":"Ganatra D, Correa OC, Garrido A, Lively S, Machhar RA, Pollock R, et al., editors. Micro-RNAs as Biomarkers for Methotrexate Treatment Response in Patients with Psoriatic Arthritis. ACR Convergence 2024; 2024: Arthritis & Rheumatology."},{"key":"410_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112239","volume":"134","author":"G De Benedittis","year":"2024","unstructured":"De Benedittis G, D\u2019Antonio A, Latini A, Morgante C, Conigliaro P, Triggianese P, et al. Study of lncRNAs expression profile in the response to biological drugs in Psoriatic Arthritis: MEG3 could be a potential genomic biomarker of therapy efficacy. Int Immunopharmacol. 2024;134:112239.","journal-title":"Int Immunopharmacol"},{"key":"410_CR69","doi-asserted-by":"publisher","first-page":"866","DOI":"10.3899\/jrheum.121162","volume":"40","author":"V Chandran","year":"2013","unstructured":"Chandran V, Shen H, Pollock RA, Pellett FJ, Carty A, Cook RJ, et al. Soluble biomarkers associated with response to treatment with tumor necrosis factor inhibitors in psoriatic arthritis. J Rheumatol. 2013;40:866\u201371.","journal-title":"J Rheumatol"},{"key":"410_CR70","doi-asserted-by":"publisher","first-page":"e12556","DOI":"10.1371\/journal.pone.0012556","volume":"5","author":"AW van Kuijk","year":"2010","unstructured":"van Kuijk AW, DeGroot J, Koeman RC, Sakkee N, Baeten DL, Gerlag DM, et al. Soluble biomarkers of cartilage and bone metabolism in early proof of concept trials in psoriatic arthritis: effects of adalimumab versus placebo. PLoS One. 2010;5:e12556.","journal-title":"PLoS One"},{"key":"410_CR71","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.3899\/jrheum.2024-0396","volume":"51","author":"R Offenheim","year":"2024","unstructured":"Offenheim R, Cruz-Correa OF, Ganatra D, Gladman DD. Candidate Biomarkers for Response to Treatment in Psoriatic Disease. J Rheumatol. 2024;51:1176\u201386.","journal-title":"J Rheumatol"},{"key":"410_CR72","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1002\/prca.201500051","volume":"10","author":"ES Collins","year":"2016","unstructured":"Collins ES, Butt AQ, Gibson DS, Dunn MJ, Fearon U, van Kuijk AW, et al. A clinically based protein discovery strategy to identify potential biomarkers of response to anti-TNF-\u03b1 treatment of psoriatic arthritis. Proteomics Clin Appl. 2016;10:645\u201362.","journal-title":"Proteomics Clin Appl"},{"key":"410_CR73","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1136\/annrheumdis-2014-205417","volume":"75","author":"OS Ademowo","year":"2016","unstructured":"Ademowo OS, Hernandez B, Collins E, Rooney C, Fearon U, van Kuijk AW, et al. Discovery and confirmation of a protein biomarker panel with potential to predict response to biological therapy in psoriatic arthritis. Ann Rheum Dis. 2016;75:234\u201341.","journal-title":"Ann Rheum Dis"},{"key":"410_CR74","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1136\/annrheumdis-2012-201697","volume":"72","author":"CL Wagner","year":"2013","unstructured":"Wagner CL, Visvanathan S, Elashoff M, McInnes IB, Mease PJ, Krueger GG, et al. Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab. Ann Rheum Dis. 2013;72:83\u20138.","journal-title":"Ann Rheum Dis"},{"key":"410_CR75","doi-asserted-by":"publisher","first-page":"e12556","DOI":"10.1136\/rmdopen-2023-003042","volume":"9","author":"M Cardner","year":"2023","unstructured":"Cardner M, Tuckwell D, Kostikova A, Forrer P, Siegel RM, Marti A, et al. Analysis of serum proteomics data identifies a quantitative association between beta-defensin 2 at baseline and clinical response to IL-17 blockade in psoriatic arthritis. RMD Open. 2023;9:e12556.","journal-title":"RMD Open"},{"key":"410_CR76","doi-asserted-by":"publisher","first-page":"a000588","DOI":"10.1101\/mcs.a000588","volume":"1","author":"CB Clish","year":"2015","unstructured":"Clish CB. Metabolomics: an emerging but powerful tool for precision medicine. Cold Spring Harb Mol Case Stud. 2015;1:a000588.","journal-title":"Cold Spring Harb Mol Case Stud"},{"key":"410_CR77","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1002\/art.37921","volume":"65","author":"SR Kapoor","year":"2013","unstructured":"Kapoor SR, Filer A, Fitzpatrick MA, Fisher BA, Taylor PC, Buckley CD, et al. Metabolic profiling predicts response to anti-tumor necrosis factor \u03b1 therapy in patients with rheumatoid arthritis. Arthritis Rheum. 2013;65:1448\u201356.","journal-title":"Arthritis Rheum"},{"key":"410_CR78","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3899\/jrheum.2024-0260","volume":"51","author":"V Chandran","year":"2024","unstructured":"Chandran V, Liao W, de Vlam K. Biomarkers in Psoriasis and Psoriatic Arthritis: Where Are We Now? J Rheumatol. 2024;51:74\u20136.","journal-title":"J Rheumatol"},{"key":"410_CR79","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2023.1199087","volume":"14","author":"JS Wekesa","year":"2023","unstructured":"Wekesa JS, Kimwele M. A review of multi-omics data integration through deep learning approaches for disease diagnosis, prognosis, and treatment. Front Genet. 2023;14:1199087.","journal-title":"Front Genet"},{"key":"410_CR80","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.cell.2024.02.041","volume":"187","author":"A Passaro","year":"2024","unstructured":"Passaro A, Al Bakir M, Hamilton EG, Diehn M, Andr\u00e9 F, Roy-Chowdhuri S, et al. Cancer biomarkers: Emerging trends and clinical implications for personalized treatment. Cell. 2024;187:1617\u201335.","journal-title":"Cell"},{"key":"410_CR81","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.1111\/jdv.15431","volume":"33","author":"MC Ovejero-Benito","year":"2019","unstructured":"Ovejero-Benito MC, Mu\u00f1oz-Aceituno E, Reolid A, Fisas LH, Llamas-Velasco M, Prieto-P\u00e9rez R, et al. Polymorphisms associated with anti-TNF drugs response in patients with psoriasis and psoriatic arthritis. Journal of the European Academy of Dermatology and Venereology. 2019;33:e175\u2013e7.","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"key":"410_CR82","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.3899\/jrheum.110980","volume":"39","author":"J Ram\u00edrez","year":"2012","unstructured":"Ram\u00edrez J, Fern\u00e1ndez-Sueiro JL, L\u00f3pez-Mej\u00edas R, Montilla C, Arias M, Moll C, et al. FCGR2A\/CD32A and FCGR3A\/CD16A variants and EULAR response to tumor necrosis factor-\u03b1 blockers in psoriatic arthritis: a longitudinal study with 6 months of followup. J Rheumatol. 2012;39:1035\u201341.","journal-title":"J Rheumatol"},{"key":"410_CR83","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.jbspin.2012.02.003","volume":"79","author":"MJ Morales-Lara","year":"2012","unstructured":"Morales-Lara MJ, Ca\u00f1ete JD, Torres-Moreno D, Hern\u00e1ndez MV, Pedrero F, Celis R, et al. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis. Joint Bone Spine. 2012;79:591\u20136.","journal-title":"Joint Bone Spine"},{"key":"410_CR84","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1038\/jid.2014.123","volume":"134","author":"G Murdaca","year":"2014","unstructured":"Murdaca G, Gulli R, Span\u00f2 F, Lantieri F, Burlando M, Parodi A, et al. TNF-\u03b1 gene polymorphisms: association with disease susceptibility and response to anti-TNF-\u03b1 treatment in psoriatic arthritis. J Invest Dermatol. 2014;134:2503\u20139.","journal-title":"J Invest Dermatol"},{"key":"410_CR85","doi-asserted-by":"crossref","unstructured":"Machhar R, Ye JY, Chandran V, Gladman DD, editors. Role of miRNA-21-5p As a Potential Biomarker for the Inflammation Pathway in Psoriatic Disease and Response to Methotrexate Treatment. 2018 ACR\/ARHP Annual Meeting; 2018: Arthritis & Rheumatology.","DOI":"10.1136\/annrheumdis-2019-eular.7869"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41397-026-00410-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41397-026-00410-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41397-026-00410-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T07:04:47Z","timestamp":1782198287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41397-026-00410-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":85,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["410"],"URL":"https:\/\/doi.org\/10.1038\/s41397-026-00410-8","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"assertion":[{"value":"24 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JB reports a research grant award from Pfizer (awarded 2018) and in the last 3 years travel\/conference fees from UCB and Fresenius Kabi. PH attended educational meetings and conferences sponsored by Johnson and Johnson, UCB and Novartis, speaker fees from UCB, Novartis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}